Decoding Personalized Nutritional, Microbiome and Host Patterns Impacting Clinical and Prognostic Features in Crohn's Disease

Prior treatment

• Chronic treatment with any oral/systemic immunosuppressive or anti-inflammatory drugs (e.g. steroids, 5-aminosalicylic acid, immunomodulators, biologics, etc.). Patients receiving these drugs as inhalors/creams/ointments should not be excluded from the study.
• Use of systemic antibiotics, probiotics or NSAIDs during 30 days prior to enrollment.
• Gut-related surgery, including bariatric surgery.
  • Control group not undergoing colonoscopy:
• Chronic treatment with any oral/systemic immunosuppressive or anti-inflammatory drugs (e.g. steroids, 5-aminosalicylic acid, immunomodulators, biologics, etc.). Patients receiving these drugs as inhalors/creams/ointments should not be excluded from the study.
• Use of systemic antibiotics, probiotics or NSAIDs during 30 days prior to enrollment.
• Gut-related surgery, including bariatric surgery.

Other illness

• Any known autoimmune or rheumatologic disease.
• Chronic gastro-intestinal disorder (e.g. celiac disease, eosinophilic esophagitis, collagenous gastritis, autoimmune gastritis, etc.).
• Past or present history of malignancy.
• Any known autoimmune or rheumatologic disease.
• Chronic gastro-intestinal disorder (e.g. celiac disease, eosinophilic esophagitis, collagenous gastritis, autoimmune gastritis, etc.).
• Past or present history of malignancy.

Age

• CD study group
  • Any known autoimmune or rheumatologic disease.
  • Chronic gastro-intestinal disorder (e.g. celiac disease, eosinophilic esophagitis, collagenous gastritis, autoimmune gastritis, etc.).
  • Past or present history of malignancy.
  • Primary immunodeficiency.
  • Pregnancy in the last 6 months, breastfeeding.
  • Morbid obesity (BMI \> 95th percentile for their age and gender).
  • Following particular dietary regimen/dietitian consultation/participation in another study.
  • Chronic treatment with any oral/systemic immunosuppressive or anti-inflammatory drugs (e.g. steroids, 5-aminosalicylic acid, immunomodulators, biologics, etc.). Patients receiving these drugs as inhalors/creams/ointments should not be excluded from the study.
  • Use of systemic antibiotics, probiotics or NSAIDs during 30 days prior to enrollment.
  • Gut-related surgery, including bariatric surgery.
  • Inability of the participant and nuclear family to follow and utilize the smartphone application.
  • Control group undergoing endoscopy:
• Morbid obesity (BMI \> 95th percentile for their age and gender).
• Morbid obesity (BMI \> 95th percentile for their age and gender).

Other

• Primary immunodeficiency.
• Pregnancy in the last 6 months, breastfeeding.
• Following particular dietary regimen/dietitian consultation/participation in another study.
• Primary immunodeficiency.
• Pregnancy in the last 6 months, breastfeeding.
• Following particular dietary regimen/dietitian consultation/participation in another study.

• CD study group - 'Consent form - Part 1'
  • Children with clinical suspicion for CD.
  • Between 6 and 18 years of age.
  • Naïve to any medical or nutritional intervention.
  • CD study group - 'Consent form - Part 2'
• Children with CD confirmed by endoscopy (and based on accepted criteria)
• Between 6 and 18 years of age.
• Naïve to any medical or nutritional intervention.
  • Control group undergoing endoscopy children between 6 and 18 years of age undergoing colonoscopy for non-specific abdominal pain or other non-inflammatory gastrointestinal conditions.
  • Control group not undergoing colonoscopy
• Children with no symptoms or signs of gastrointestinal disease and no known medical conditions.
• Children between 6 and 18 years of age. These children will be recruited from general pediatric clinics (children attending for routine check-up), orthopedic clinics, ophthalmology clinics or schools.